Literature DB >> 12808227

Change in double product during stepwise incremental exercise.

Kyu Tae Kim1, Seung Wook Choi, Kazufumi Takahashi, Takashi Kurokawa, Masahiro Yamasaki.   

Abstract

The purpose of this study was to observe the change in double product with increases in the intensity of bicycle exercise. Eleven young male adults participated in this study. The subjects performed graded bicycling exercise increasing 20 watts every 2 min from 0 watts until the heart rate (HR) reached 170 beats.min(-1). During exercise systolic blood pressure (SBP) and HR were continuously measured. Initially SBP gradually increased with the increase in workload, but when the intensity of exercise became even higher, the rate of increase slowed. On the other hand, the increase in HR was very small during the initial 5 min of exercise and when the intensity of exercise increased, the rate of increase of HR became higher. The polygonal regression analyses on the relation of double product to elapsed time revealed clear break-points. On average, the break-point of double product was 6.6 min (56 watts). These results clearly showed that the break-point of double product with an increase in workload appeared even though the workload was relatively low.

Mesh:

Year:  2003        PMID: 12808227     DOI: 10.2114/jpa.22.143

Source DB:  PubMed          Journal:  J Physiol Anthropol Appl Human Sci        ISSN: 1345-3475


  2 in total

1.  The influence of aerobic exercise training on the double product break point in low-to-moderate risk adults.

Authors:  Trent A Hargens; Diane C Griffin; Leonard A Kaminsky; Mitchell H Whaley
Journal:  Eur J Appl Physiol       Date:  2010-09-28       Impact factor: 3.078

2.  Use of atropine in patients with recent myocardial infarction during exercise myocardial perfusion study. Use of atropine during exercise myocardial perfusion SPECT.

Authors:  S Barai; C D Patel; A Malhotra; G P Bandopadhayaya; S Gambhir; R Kumar; H Dhanapathi
Journal:  Int J Cardiovasc Imaging       Date:  2005-08       Impact factor: 2.357

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.